Results 81 to 90 of about 163,161 (264)

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki   +9 more
wiley   +1 more source

Relationship Between Gastroesophageal Reflux Disease-Related Symptoms and Clinicopathologic Characteristics and Long-Term Survival of Patients with Esophageal Adenocarcinoma in China

open access: yesZhongliu Fangzhi Yanjiu
ObjectiveTo investigatethe relationship between gastroesophageal reflux disease (GERD) symptoms and clinicopathological characteristics, p53 expression, and survival of Chinese patients with esophageal adenocarcinoma. MethodsA total of 3882 patients with
Kan ZHONG   +20 more
doaj   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu   +9 more
wiley   +1 more source

History, Experience, Opportunities, and Challenges in Esophageal Cancer Prevention and Treatment in Linxian, Henan Province, A High Incidence Area for Esophageal Cancer

open access: yesZhongliu Fangzhi Yanjiu
Linxian County in Henan Province, Northern China is known as the region with the highest incidence and mortality rate of esophageal cancer worldwide.
Lidong WANG   +13 more
doaj   +1 more source

Relationship Between Hospital Volume and Outcomes of Minimally Invasive Esophagectomy for Esophageal Cancer: Analysis of the National Clinical Database in Japan

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
According to multivariable analysis conducted using a hierarchical logistic regression model, using VHH as the reference group, the odds ratios for mortality by hospital volume category were as follows: VLH, 2.70 (p < 0.0001); LH, 1.72 (p = 0.052); MH, 1.70 (p = 0.034); and HH, 1.43 (p = 0.173).
Soji Ozawa   +8 more
wiley   +1 more source

Machine learning technique-based four-autoantibody test for early detection of esophageal squamous cell carcinoma: a multicenter, retrospective study with a nested case–control study

open access: yesBMC Medicine
Background Autoantibodies represent promising diagnostic blood-based biomarkers that may be generated prior to the first clinically detectable signs of cancers.
Yi-Wei Xu   +10 more
doaj   +1 more source

Sex‐Based Body Composition Changes in Patients With Rectal Cancer Undergoing Preoperative Chemoradiotherapy: A Prospective Observational Study

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This prospective study observed that preoperative chemoradiotherapy for rectal cancer was associated with reductions in body fat and grip strength, which appeared to be more pronounced in female patients. These findings suggest that sex‐sensitive nutritional and exercise support may be beneficial to help maintain muscle mass and physical function ...
Shinya Abe   +9 more
wiley   +1 more source

Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab

open access: yesNature Communications
The combination of toripalimab (an anti-PD-1 antibody) with definitive chemoradiotherapy (CRT) demonstrated encouraging efficacy against locally advanced esophageal squamous cell carcinoma (ESCC) in the EC-CRT-001 phase II trial (NCT04005170).
Baoqing Chen   +12 more
doaj   +1 more source

Higher 3-year recurrence-free survival rate in patients with complete pathological remission following neoadjuvant chemotherapy plus immunotherapy for esophageal cancer: a two-center, propensity score matching study

open access: yesFrontiers in Oncology
BackgroundNeoadjuvant therapy is preferentially recommended for resectable locally advanced esophageal malignancies, with patients who achieve pathological complete response (PCR) anticipated to have longer survival rates.
Hai Zhang   +12 more
doaj   +1 more source

Systematic Review and Meta‐Analysis on the Efficacy and Safety of Salvage Esophagectomy for T4 Esophageal Squamous Cell Carcinoma

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This meta‐analysis of 208 cases shows that salvage esophagectomy for cT4 esophageal squamous cell carcinoma achieves a 72% R0 resection rate, offering a curative pathway for selected patients. However, it remains a high‐risk procedure with an 18% anastomotic leak rate and 30% major complications (Clavien–Dindo ≥ III).
Makoto Sakai   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy